TY - JOUR
T1 - Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting e-cadherin via miR-9
AU - Lu, Mei Hsuan
AU - Huang, Chao Cheng
AU - Pan, Mei Ren
AU - Chen, Hong Hwa
AU - Hung, Wen Chun
PY - 2012/12/1
Y1 - 2012/12/1
N2 - Purpose: Prospero homeobox 1 (PROX1) has been shown to function as a tumor suppressor in various types of cancer. However, it promotes colon cancer progression. The aim of this study is to clarify the underlying mechanism by which PROX1 regulates tumorigenicity of colon cancer. Experimental Design: Association of PROX1 and clinicopathological features was studied by immunohistochemical staining. Pri-miR-9-2 and miR-9 were detected by quantitative real-time PCR. Assays of cell invasion, adhesion, and matrix metalloproteinase activity were used to study PROX1-mediated epithelial-mesenchymal transition (EMT). Results: PROX1 was overexpressed in 43% (59/136) of colon cancer tissues and its expression was correlated with E-cadherin downregulation (P=0.00005), advanced tumor staging (P=0.005), and lymph node metastasis (P=0.000009). Enforced expression of PROX1 in DLD-1 cells caused downregulation of E-cadherin and integrins and attenuated cell adhesion. These cells showed increase of matrix metalloproteinase activity and invasive ability. Conversely, knockdown of PROX1 in SW620 cells restored E-cadherin protein expression and reduced invasiveness. Unexpectedly, repression of E-cadherin by PROX1 was not mediated by transcriptional inhibition. We found that PROX1 bound to miR-9-2 promoter and triggered its expression to suppress E-cadherin 30UTR reporter activity and protein expression. Anti-miR-9 restored Ecadherin in SW620 cells, whereas precursor miR-9 inhibited E-cadherin in PROX1-knockdown cells. The miR-9 level was higher in tumor tissues with high PROX1/low E-cadherin than that of tumor tissues with low PROX1/high E-cadherin. Conclusions: Our results provide mechanistic insights by which PROX1 promotesEMT and colon cancer progression. Targeting of PROX1-mediated oncogenic activity may be helpful for the treatment of colon cancer.
AB - Purpose: Prospero homeobox 1 (PROX1) has been shown to function as a tumor suppressor in various types of cancer. However, it promotes colon cancer progression. The aim of this study is to clarify the underlying mechanism by which PROX1 regulates tumorigenicity of colon cancer. Experimental Design: Association of PROX1 and clinicopathological features was studied by immunohistochemical staining. Pri-miR-9-2 and miR-9 were detected by quantitative real-time PCR. Assays of cell invasion, adhesion, and matrix metalloproteinase activity were used to study PROX1-mediated epithelial-mesenchymal transition (EMT). Results: PROX1 was overexpressed in 43% (59/136) of colon cancer tissues and its expression was correlated with E-cadherin downregulation (P=0.00005), advanced tumor staging (P=0.005), and lymph node metastasis (P=0.000009). Enforced expression of PROX1 in DLD-1 cells caused downregulation of E-cadherin and integrins and attenuated cell adhesion. These cells showed increase of matrix metalloproteinase activity and invasive ability. Conversely, knockdown of PROX1 in SW620 cells restored E-cadherin protein expression and reduced invasiveness. Unexpectedly, repression of E-cadherin by PROX1 was not mediated by transcriptional inhibition. We found that PROX1 bound to miR-9-2 promoter and triggered its expression to suppress E-cadherin 30UTR reporter activity and protein expression. Anti-miR-9 restored Ecadherin in SW620 cells, whereas precursor miR-9 inhibited E-cadherin in PROX1-knockdown cells. The miR-9 level was higher in tumor tissues with high PROX1/low E-cadherin than that of tumor tissues with low PROX1/high E-cadherin. Conclusions: Our results provide mechanistic insights by which PROX1 promotesEMT and colon cancer progression. Targeting of PROX1-mediated oncogenic activity may be helpful for the treatment of colon cancer.
UR - http://www.scopus.com/inward/record.url?scp=84870360174&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-12-0832
DO - 10.1158/1078-0432.CCR-12-0832
M3 - 文章
C2 - 23045246
AN - SCOPUS:84870360174
SN - 1078-0432
VL - 18
SP - 6416
EP - 6425
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 23
ER -